DRKS00011639
Recruiting
Phase 3
Patients with Multiple Sclerosis and Severe Disabilities: Effects of Electrical Stimulation Cycling Training on Mobility an Power Performance
Zentrum für Sensomotorik der Neurologischen Klinik,Klinikum Großhadern0 sites64 target enrollmentFebruary 20, 2017
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- G35.2
- Sponsor
- Zentrum für Sensomotorik der Neurologischen Klinik,Klinikum Großhadern
- Enrollment
- 64
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis: Multiple Sklerosis
- •\-Age \> 18 y
- •\-Reduced lower extremity muscle function, Gait impairment
Exclusion Criteria
- •\-having power of attorney
- •\-no pacemaker or higher\-grade arrhythmias
- •\-no metall parts in the stimulation area
- •\-no skin allergia against electrodes
- •\-no wound or other lesions in the stimulation area
- •\-no osteoporosis, no muscle or ligament contractures, no reduced range of motion in the knee and hip joints.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trialMultiple sclerosisTherapeutic area: Diseases [C] - Nervous System Diseases [C10]Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2023-505420-62-00Hopital Fondation Adolphe De Rothschild192
Not yet recruiting
Phase 3
Treatment of Progressive Multiple Sclerosis-related Cognitive Impairment, Fatigue, and Depression Using Repetitive Transcranial Magnetic StimulatioNervous System DiseasesPACTR202403516079512Science Technology and Innovation Funding Authority60
Completed
Not Applicable
Diagnostic criteria for Multiple Sclerosis: Impact of high field Magnetic Resonance ImagingMSmultiple sclerosis1000381610012303NL-OMON40083Vrije Universiteit Medisch Centrum30
Completed
Phase 2
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialSecondary Progressive Multiple SclerosisNCT01910259University College, London445
Completed
Phase 3
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSMultiple SclerosisSpasticity, MuscleNCT03290131RVL Pharmaceuticals, Inc.536